罗莫佐单抗与地舒单抗及利塞膦酸在初用糖皮质激素患者中的疗效比较
该随机对照研究纳入新启动泼尼松龙≥15 mg/日且未接受过骨质疏松治疗的的风湿病患者,比较罗莫佐单抗、地舒单抗与双膦酸盐对糖皮质激素性骨质疏松的疗效。12个月时腰椎骨密度中位变化百分比罗莫佐单抗组最大(8.6%),地舒单抗组为3.3%,双膦酸盐组为-0.4%。结论提示罗莫佐单抗可显著增加腰椎骨密度,对糖皮质激素性骨质疏松有效。
要点
- 新启动糖皮质激素治疗患者中,罗莫佐单抗12个月腰椎骨密度中位变化百分比为8.6%,地舒单抗为3.3%,双膦酸盐为-0.4%。
- 罗莫佐单抗组骨形成标志物骨碱性磷酸酶轻度升高,而Ⅰ型前胶原N端前肽和骨钙素在三组均下降,但罗莫佐单抗组变化较小。
- 三组骨吸收标志物和尿骨质量标志物均下降。
核心结论
- 罗莫佐单抗治疗可显著增加糖皮质激素治疗患者的腰椎骨密度,提示罗莫佐单抗对糖皮质激素性骨质疏松有效。
研究设计与样本
- 随机对照研究,纳入既往未接受骨质疏松治疗且新开始泼尼松龙≥15 mg/日的风湿病患者,随机分为罗莫佐单抗组(11例)、地舒单抗组(14例)和双膦酸盐组(14例)。
- 开始糖皮质激素治疗后,每6个月测量腰椎、股骨颈和全髋骨密度,每3个月测量骨转换标志物,持续12个月。
主要发现
- 12个月时腰椎骨密度较基线变化百分比的中位数[第25至75百分位]为罗莫佐单抗组8.6[3.1-12.4]%、地舒单抗组3.3[1.5-6.2]%、双膦酸盐组-0.4[-3.4-1.1]%,罗莫佐单抗组最大。
- 骨形成标志物中,罗莫佐单抗组血清骨碱性磷酸酶轻度升高,而Ⅰ型前胶原N端前肽和骨钙素在三组均下降,但罗莫佐单抗组变化较小。
- 三组血清骨吸收标志物和尿骨质量标志物均下降。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Wnt/β-catenin signaling pathway is one of the pathogenic mechanisms of glucocorticoid-induced osteoporosis (GIOP). We previously reported the potential of inhibiting sclerostin as a treatment for GIOP. OBJECTIVE: To compare the efficacy of romosozumab (ROMO), a monoclonal antibody against sclerostin, with existing therapy for GIOP. METHODS: Patients with rheumatic diseases who had not previously received treatment for osteoporosis and were newly treated with prednisolone 15 mg/day or more were randomly assigned to receive ROMO, denosumab (DMAb), or bisphosphonates (BP). After the initiation of glucocorticoid therapy, we measured the bone mineral density (BMD) of the lumbar spine, femoral neck, and total hip every 6 months and bone turnover markers every 3 months for 12 months. RESULTS: Eleven patients were assigned to the ROMO group, 14 to the DMAb group, and 14 to the BP group. The median [25th to 75th percentile] percent change in lumbar spine BMD from baseline at 12 months was the greatest in the ROMO group (ROMO: 8.6 [3.1-12.4]%, DMAb: 3.3 [1.5-6.2]%, BP: -0.4 [-3.4-1.1]%). Among bone formation markers, serum levels of bone alkaline phosphatase were slightly elevated in the ROMO group, whereas those of N-terminal propeptide of type I procollagen and osteocalcin decreased in all 3 groups; however, these changes were smaller in the ROMO group. Serum levels of bone resorption markers and a urine bone quality marker decreased in all groups. CONCLUSION: Treatment with ROMO significantly increased lumbar spine BMD in glucocorticoid-treated patients, suggesting that ROMO is effective for GIOP. CLINICAL TRIAL NUMBER: UMIN000037239.
引用
- Kawazoe M, Kaneko K, Masuoka S, et al. Comparison of Efficacy of Romosozumab With Denosumab and Risedronate in Patients Newly Initiating Glucocorticoid Therapy. J Clin Endocrinol Metab. 2025. PMID: 39552045. doi:10.1210/clinem/dgae810
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。